|
1
|
Schatten H: Brief overview of prostate
cancer statistics, grading, diagnosis and treatment strategies. Adv
Exp Med Biol. 1095:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Horiguchi M, Uno H and Wei LJ: Evaluating
noninferiority with clinically interpretable statistics for the
PROSELICA study to assess treatment efficacy of a reduced dose of
cabazitaxel for treating metastatic prostate cancer. J Clin Oncol.
36:825–826. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lunardi A, Ala U, Epping MT, Salmena L,
Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack
EC, et al: A co‑clinical approach identifies mechanisms and
potential therapies for androgen deprivation resistance in prostate
cancer. Nat Genet. 45:747–755. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu N, Zhang Z, Chen P, Zhong Y, Cai X, Hu
H, Yang Y, Zhang J, Li K, Ge J, et al: Tetramethylpyrazine (TMP),
an active ingredient of Chinese herb medicine chuanxiong,
attenuates the degeneration of trabecular meshwork through
SDF-1/CXCR4 axis. PLoS One. 10:e01330552015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeng Z, Zhu W, Zhou X, Jin Z, Liu H, Chen
X, Pan J, Demura H, Naruse M and Shi Y: Tetramethylpyrazine, a
Chinese drug, blocks coronary vasoconstriction by endothelin-1 and
decreases plasma endothelin-1 levels in experimental animals. J
Cardiovasc Pharmacol. 31(Suppl 1): S313–S316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang HH, Liu FB, Ruan Z, Zheng J, Su YJ
and Wang J: Tetramethylpyrazine (TMPZ) triggers S-phase arrest and
mitochondria-dependent apoptosis in lung cancer cells. Neoplasma.
65:367–375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S, Lei T and Zhang M: The reversal
effect and its mechanisms of tetramethylpyrazine on multidrug
resistance in human bladder cancer. PLoS One. 11:e01577592016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH:
Tetramethylpyrazine reverses multidrug resistance in breast cancer
cells through regulating the expression and function of
P-glycoprotein. Med Oncol. 29:534–538. 2012. View Article : Google Scholar
|
|
9
|
Yi B, Liu D, He M, Li Q, Liu T and Shao J:
Role of the ROS/AMPK signaling pathway in
tetramethylpyrazine-induced apoptosis in gastric cancer cells.
Oncol Lett. 6:583–589. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Ji Z, Yan W, Zhou Z, Li H and Xiao
Y: Tetramethylpyrazine inhibits prostate cancer progression by
downregulation of forkhead box M1. Oncol Rep. 38:837–842. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rafiee A, Riazi‑Rad F, Havaskary M and
Nuri F: Long noncoding RNAs: Regulation, function and cancer.
Biotechnol Genet Eng Rev. 34:153–180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Josipovic I, Pflüger B, Fork C, Vasconez
AE, Oo JA, Hitzel J, Seredinski S, Gamen E, Heringdorf DMZ, Chen W,
et al: Long noncoding RNA LISPR1 is required for S1P signaling and
endo-thelial cell function. J Mol Cell Cardiol. 116:57–68. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Magistri M, Faghihi MA, St Laurent G III
and Wahlestedt C: Regulation of chromatin structure by long
noncoding RNAs: Focus on natural antisense transcripts. Trends
Genet. 28:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li W, Sun M, Zang C, Ma P, He J, Zhang M,
Huang Z, Ding Y and Shu Y: Upregulated long non-coding RNA
AGAP2-AS1 represses LATS2 and KLF2 expression through interacting
with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell Death
Dis. 7:e22252016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen C, Feng Y and Wang X: LncRNA ZEB1-AS1
expression in cancer prognosis: Review and meta-analysis. Clin Chim
Acta. 484:265–271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Kent WJ, Sugnet CW, Furey TS, Roskin KM,
Pringle TH, Zahler AM and Haussler D: The human genome browser at
UCSC. Genome Res. 12:996–1006. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar
|
|
21
|
Lv C, Zhao G, Sun X, Wang P, Xie N, Luo J
and Tong T: Acetylation of FOXM1 is essential for its
transactivation and tumor growth stimulation. Oncotarget.
7:60366–60382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Tang Y, Cole PA and Marmorstein R:
Structure and chemistry of the p300/CBP and Rtt109 histone
acetyltrans-ferases: Implications for histone acetyltransferase
evolution and function. Curr Opin Struct Biol. 18:741–747. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Curry EA III and Sweeney CJ: Resistance to
luteinizing hormone releasing hormone agonist therapy for
metastatic prostate cancer. J Urol. 168:1932002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McCarty MF: Current prospects for
controlling cancer growth with non-cytotoxic agents-nutrients,
phytochemicals, herbal extracts, and available drugs. Med
Hypotheses. 56:137–154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muhamad N, Plengsuriyakarn T and
Na-Bangchang K: Application of active targeting nanoparticle
delivery system for chemotherapeutic drugs and traditional/herbal
medicines in cancer therapy: A systematic review. Int J
Nanomedicine. 13:3921–3935. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vinayak M: Molecular action of herbal
antioxidants in regulation of cancer growth: Scope for novel
anticancer drugs. Nutr Cancer. 70:1199–1209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo M, Liu Y and Shi D: Cardiovascular
actions and therapeutic potential of tetramethylpyrazine (Active
Component Isolated from Rhizoma Chuanxiong): Roles and mechanisms.
Biomed Res Int. 2016:24303292016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu JZ, Huang JH, Xiao ZM, Li JH, Li XM and
Lu HB: Tetramethylpyrazine accelerates the function recovery of
traumatic spinal cord in rat model by attenuating inflammation. J
Neurol Sci. 324:94–99. 2013. View Article : Google Scholar
|
|
29
|
Cao J, Miao Q, Miao S, Bi L, Zhang S, Yang
Q, Zhou X, Zhang M, Xie Y, Zhang J and Wang S: Tetramethylpyrazine
(TMP) exerts antitumor effects by inducing apoptosis and autophagy
in hepa-tocellular carcinoma. Int Immunopharmacol. 26:212–220.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jia Y, Wang Z, Zang A, Jiao S, Chen S and
Fu Y: Tetramethylpyrazine inhibits tumor growth of lung cancer
through disrupting angiogenesis via BMP/Smad/Id-1 signaling. Int J
Oncol. 48:2079–2086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jadaliha M, Gholamalamdari O, Tang W,
Zhang Y, Petracovici A, Hao Q, Tariq A, Kim TG, Holton SE, Singh
DK, et al: A natural antisense lncRNA controls breast cancer
progression by promoting tumor suppressor gene mRNA stability. PLoS
Genet. 14:e10078022018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pian L, Wen X, Kang L, Li Z, Nie Y, Du Z,
Yu D, Zhou L, Jia L, Chen N, et al: Targeting the IGF1R pathway in
breast cancer using antisense lncRNA-mediated promoter cis
competition. Mol Ther Nucleic Acids. 12:105–117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su W, Xu M, Chen X, Chen N, Gong J, Nie L,
Li L, Li X, Zhang M and Zhou Q: Long noncoding RNA ZEB1-AS1
epigenetically regulates the expressions of ZEB1 and downstream
molecules in prostate cancer. Mol Cancer. 16:1422017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Belau F, Metzner K, Christ T, Ravens U,
Schaefer M, Künzel S, Li W, Wettwer E, Dobrev D, El-Armouche A and
Kämmerer S: DPP10 is a new regulator of Nav1.5 channels in human
heart. Int J Cardiol. 284:68–73. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pérez‑Peña J, Győrffy B, Amir E, Pandiella
A and Ocaña A: Epigenetic modulation of FOXM1-gene interacting
network by BET inhibitors in breast cancer. Breast Cancer Res
Treat. 172:725–732. 2018. View Article : Google Scholar
|
|
36
|
Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q,
Xu N, Cheng Q, Qian Y, Huang R, et al: Epigenetically modulated
FOXM1 suppresses dendritic cell maturation in pancreatic cancer and
colon cancer. Mol Oncol. 13:873–893. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu
JC, Yan PS, Nephew KP and Huang TH: Triple analysis of the cancer
epigenome: An integrated microarray system for assessing gene
expression, DNA methylation, and histone acetylation. Cancer Res.
63:2164–2171. 2003.PubMed/NCBI
|
|
38
|
Tang RZ, Zhu JJ, Yang FF, Zhang YP, Xie
SA, Liu YF, Yao WJ, Pang W, Han LL, Kong W, et al: DNA
methyltransferase 1 and Krüppel‑like factor 4 axis regulates
macrophage inflammation and atherosclerosis. J Mol Cell Cardiol.
128:11–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu L, He X, Zhao M, Yang S, Wang S, Yu X,
Liu J and Zang W: Regulation of DNA methylation and 2-OG/TET
signaling by choline alleviated cardiac hypertrophy in
spontaneously hypertensive rats. J Mol Cell Cardiol. 128:26–37.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wan G, Hu X, Liu Y, Han C, Sood AK, Calin
GA, Zhang X and Lu X: A novel non-coding RNA lncRNA-JADE connects
DNA damage signalling to histone H4 acetylation. EMBO J.
32:2833–2847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li D, Bi FF, Cao JM, Cao C, Liu B and Yang
Q: Regulation of DNA methyltransferase 1 transcription in
BRCA1-mutated breast cancer: A novel crosstalk between E2F1 motif
hypermethylation and loss of histone H3 lysine 9 acetylation. Mol
Cancer. 13:262014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu X, Yin Y, Tang J, Xie Y, Han Z, Zhang
X, Liu Q, Qin X, Huang X and Sun B: Long non-coding RNA Myd88
promotes growth and metastasis in hepatocellular carcinoma via
regulating Myd88 expression through H3K27 modification. Cell Death
Dis. 8:e31242017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong H, Wang W, Mo S, Liu Q, Chen X, Chen
R, Zhang Y, Zou K, Ye M, He X, et al: Long non-coding RNA SNHG14
induces trastuzumab resistance of breast cancer via regulating
PABPC1 expression through H3K27 acetylation. J Cell Mol Med.
22:4935–4947. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Das C, Lucia MS, Hansen KC and Tyler JK:
CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature.
459:113–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ghosh TK, Aparicio-Sánchez JJ, Buxton S,
Ketley A, Mohamed T, Rutland CS, Loughna S and Brook JD:
Acetylation of TBX5 by KAT2B and KAT2A regulates heart and limb
development. J Mol Cell Cardiol. 114:185–198. 2018. View Article : Google Scholar
|
|
46
|
Wang YM, Gu ML, Meng FS, Jiao WR, Zhou XX,
Yao HP and Ji F: Histone acetyltransferase p300/CBP inhibitor C646
blocks the survival and invasion pathways of gastric cancer cell
lines. Int J Oncol. 51:1860–1868. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kouzarides T: SnapShot: Histone-modifying
enzymes. Cell. 131:8222007. View Article : Google Scholar : PubMed/NCBI
|
